


Development of First-in-Class NK Cell Engagers Targeting Trop-2NKp46 Incorporating ADCC Maximizing Fc Variants for the Treatment of Triple-Negative Breast Cancer

Korea University

Disease Area	Cancer
Product Type	NK cell engager
Indication	Triple-negative breast cancer (TNBC)
Target	Trop-2, NKp46 and CD16A
Mechanism of Action	Maximized NK cell activation → Efficient clearance of Trop-2 expressed TNBC
Competitiveness	First-in-Class <ul style="list-style-type: none">- Trop-2 target NK cell engager.- Maximized NK cell recruitment through CD16A×NKp46×B7-H6.- Bispecific antibody format that can be produced by simple bioprocessing steps.
Development Stage	Hit to lead
Route of Administration	Intravenous
Key Data	<div><div>Maximization of NK cell cytotoxicity</div><div><div>① Fc variants that show world-best ADCC activity</div><div>② NKp46-targeting antibody</div><div>③ Improved NKp30 binding B7-H6 variants</div></div><div>↓</div><div>Completed identification of first-in-class leading NK cell engager for triple-negative breast cancer treatment</div></div> <div></div>
IP	<ul style="list-style-type: none">• [CD16A binding Fc] Patent No. 10-2021-0124554 / 10-2021-0124555 / 10-2021-0124556 / 10-2022-0113489 / PCT-KR2022-013476 / PCT-KR2022-013481• [NKp46 binding antibody] Patent No. 10-2024-0025467• [B7-H6 variants]Patent No. 10-2023-0077426 / PCT-KR2023-008393